Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Kazi, Julhash U ^a,b   Kabir, Nuzhat N ^b   Rönnstrand, Lars ^a  

^a LUND UNIVERSITY   (Sweden)

^b KN Biomedical Research Institute   (Bangladesh)

Author keywords

B CLL; CLL; CSF1R; FLT3; KIT; M CSFR; PDGFR

Indexed keywords

7 HYDROXYSTAUROSPORINE; APRINOCARSEN; BRYOSTATIN 1; DEXAMETHASONE; ENZASTAURIN; FLT3 LIGAND; FLUDARABINE; MESSENGER RNA; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SAFINGOL; STAUROSPORINE; STEM CELL FACTOR RECEPTOR;

APOPTOSIS; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; ENZYMOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; PROTEIN KINASE C;

MLCS; MLOWN;

EID: 84886445247     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0757-7     Document Type: Review

References (80)

1. Kabir NN, Kazi JU. Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity. Genet Mol Biol. 2011;34(4):587-91. doi: 10.1590/S1415-47572011005000035.
2. Kazi JU, Kabir NN, Soh JW. Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. Gene. 2008;410(1):147-53. doi: 10.1016/j.gene.2007.12.003.
3. Inoue M, Kishimoto A, Takai Y, Nishizuka Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem. 1977;252(21):7610-6. (Pubitemid 8227337)
4. Kazi JU. The mechanism of protein kinase C regulation. Frontiers Biol. 2011;6(4):328-36. doi: 10.1007/s11515-011-1070-5.
5. Kazi JU, Soh JW. Role of regulatory domain mutants of PKC isoforms in c-fos induction. Bull Korean Chem Soc. 2008;29(1):252-4.
6. Kazi JU, Soh JW. Induction of the nuclear proto-oncogene c-fos by the phorbol ester TPA and v-H-Ras. Mol Cells. 2008;26(5):462-7.
7. Rodriguez-Vicente AE, Diaz MG, Hernandez-Rivas JM. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet. 2013;206(3):49-62. doi: 10.1016/j.cancergen.2013.01.003.
8. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev. 2008;88(4):1341-78. doi: 10.1152/physrev.00034.2007.
9. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005;121(2):271-80. doi: 10.1016/j.cell.2005.02.019. (Pubitemid 40546394)
10. Kazi JU, Kim CR, Soh JW. Subcellular localization of diacylglycerol- responsive protein kinase C isoforms in HeLa cells. Bull Korean Chem Soc. 2009;30(9):1981-4.
11. Kazi JU, Soh JW. Isoform-specific translocation of PKC isoforms in NIH3T3 cells by TPA. Biochem Biophys Res Commun. 2007;364(2):231-7. doi: 10.1016/j.bbrc.2007.09.123. (Pubitemid 47633406)
12. Hocevar BA, Fields AP. Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. J Biol Chem. 1991;266(1):28-33. (Pubitemid 21906084)
13. Sakai N, Sasaki K, Ikegaki N, Shirai Y, Ono Y, Saito N. Direct visualization of the translocation of the gamma-subspecies of protein kinase C in living cells using fusion proteins with green fluorescent protein. J Cell Biol. 1997;139(6):1465-76. (Pubitemid 28013667)
14. Looby E, Long A, Kelleher D, Volkov Y. Bile acid deoxycholate induces differential subcellular localisation of the PKC isoenzymes beta 1, epsilon and delta in colonic epithelial cells in a sodium butyrate insensitive manner. Int J Cancer. 2005;114(6):887-95. doi: 10.1002/ijc.20803.
15. Goodnight JA, Mischak H, Kolch W, Mushinski JF. Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. Isoform-specific association with microfilaments, Golgi, endoplasmic reticulum, and nuclear and cell membranes. J Biol Chem. 1995;270(17):9991-10001.
16. Redig AJ, Platanias LC. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. J Interferon Cytokine Res. 2007;27(8):623-36. doi: 10.1089/jir2007.0007.
17. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006;235(1):1-10. doi: 10.1016/j.canlet.2005. 03.033.
18. Leirdal M, Sioud M. Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells. Br J Cancer. 1999;80(10):1558-64. doi: 10.1038/sj.bjc.6690560. (Pubitemid 29308634)
19. Detjen KM, Brembeck FH, Welzel M, Kaiser A, Haller H, Wiedenmann B, Rosewicz S. Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J Cell Sci. 2000;113(17):3025- 35.
20. Scaglione-Sewell B, Abraham C, Bissonnette M, Skarosi SF, Hart J, Davidson NO, Wali RK, Davis BH, Sitrin M, Brasitus TA. Decreased PKC-alpha expression increases cellular proliferation, decreases differentiation, and enhances the transformed phenotype of CaCo-2 cells. Cancer Res. 1998;58(5):1074-81. (Pubitemid 28182482)
21. Kabir NN, Rönnstrand L, Kazi JU. Protein kinase C expression is deregulated in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(10):2288-90. doi: 10.3109/10428194.2013.769220.
22. Marengo B, De Ciucis C, Ricciarelli R, Pronzato MA, Marinari UM, Domenicotti C. Protein kinase C: an attractive target for cancer therapy. Cancers. 2011;3(1):531-67. doi: 10.3390/cancers3010531.
23. Zum Buschenfelde CM, Wagner M, Lutzny G, Oelsner M, Feuerstacke Y, Decker T, Bogner C, Peschel C, Ringshausen I. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia. 2010;24(1):141-52. doi: 10.1038/leu.2009.216.
24. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, Decker T. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100(10):3741-8. doi: 10.1182/blood-2002-02-0539. (Pubitemid 35303946)
25. Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B, Joubert D. Invasive human pituitary tumors express a point-mutated alpha-protein kinase-C. J Clin Endocrinol Metab. 1993;77(5):1125-9. (Pubitemid 23345456)
26. Prevostel C, Martin A, Alvaro V, Jaffiol C, Joubert D. Protein kinase C alpha and tumorigenesis of the endocrine gland. Horm Res. 1997;47(4-6):140-4. (Pubitemid 27196446)
27. Vallentin A, Lo TC, Joubert D. A single point mutation in the V3 region affects protein kinase Calpha targeting and accumulation at cell-cell contacts. Mol Cell Biol. 2001;21(10):3351-63. doi: 10.1128/MCB.21.10.3351-3363.2001. (Pubitemid 32381771)
28. Zhu Y, Dong Q, Tan BJ, Lim WG, Zhou S, Duan W. The PKCalpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer Res. 2005;65(11):4520-4. doi: 10.1158/0008-5472.CAN-04-4506. (Pubitemid 40740786)
29. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99-105. doi: 10.1111/j.1440-0960.2010.00626.x.
30. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004;64(9):3243-55. (Pubitemid 38581429)
31. Lee WY, Hampson P, Coulthard L, Ali F, Salmon M, Lord JM, Scheel-Toellner D. Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. J Biol Chem. 2010;285(31):23889-98. doi: 10.1074/jbc.M109.041962.
32. Kazi JU, Rönnstrand L. Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling. PLoS ONE. 2012;7(12):e53509. doi: 10.1371/journal.pone.0053509.
33. Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L. Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3. J Biol Chem. 2012;287(43):36509-17. doi: 10.1074/jbc.M112.376111.
34. Lin DC, Yin T, Koren-Michowitz M, Ding LW, Gueller S, Gery S, Tabayashi T, Bergholz U, Kazi JU, Rönnstrand L, Stocking C, Koeffler HP. Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood. 2012;120(16):3310-7. doi: 10.1182/blood-2011-10-388611.
35. Kazi JU, Rönnstrand L. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol. 2013;7(3):693-703. doi: 10.1016/j.molonc.2013.02.020.
36. Kazi JU, Rönnstrand L. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Mol Oncol. 2013;7(3):402-18. doi: 10.1016/j.molonc.2012.11. 003.
37. Kazi JU, Vaapil M, Agarwal S, Bracco E, Pahlman S, Rönnstrand L. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal. 2013;25(9):1852-60. doi: 10.1016/j.cellsig. 2013.05.016.
38. Heiss E, Masson K, Sundberg C, Pedersen M, Sun J, Bengtsson S, Rönnstrand L. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood. 2006;108(5):1542-50. doi: 10.1182/blood-2005-07-008896. (Pubitemid 44316119)
39. Kabir NN, Rönnstrand L, Kazi JU. Deregulation of protein phosphatase expression in acute myeloid leukemia. Med Oncol. 2013;30(2):517. doi: 10.1007/s12032-013-0517-8.
40. Alimandi M, Heidaran MA, Gutkind JS, Zhang J, Ellmore N, Valius M, Kazlauskas A, Pierce JH, Li W. PLC-gamma activation is required for PDGF-betaR-mediated mitogenesis and monocytic differentiation of myeloid progenitor cells. Oncogene. 1997;15(5):585-93. doi: 10.1038/sj.onc.1201221. (Pubitemid 27384736)
41. Salhany KE, Robinson-Benion C, Candia AF, Pledger WJ, Holt JT. Differential induction of the c-fos promoter through distinct PDGF receptor-mediated signaling pathways. J Cell Physiol. 1992;150(2):386-95. doi: 10.1002/jcp.1041500223.
42. Choudhury GG, Biswas P, Grandaliano G, Abboud HE. Involvement of PKC-alpha in PDGF-mediated mitogenic signaling in human mesangial cells. Am J Physiol. 1993;265(5 Pt 2):F634-42.
43. Neri LM, Billi AM, Manzoli L, Rubbini S, Gilmour RS, Cocco L, Martelli AM. Selective nuclear translocation of protein kinase C alpha in Swiss 3T3 cells treated with IGF-I PDGF and EGF. FEBS lett. 1994;347(1):63-8. (Pubitemid 24205032)
44. Leng L, Du B, Consigli S, McCaffrey TA. Translocation of protein kinase C-delta by PDGF in cultured vascular smooth muscle cells: inhibition by TGF-beta 1. Artery. 1996;22(3):140-54. (Pubitemid 26338895)
45. Blume-Jensen P, Siegbahn A, Stabel S, Heldin CH, Rönnstrand L. Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. EMBO J. 1993;12(11):4199-209. (Pubitemid 23302034)
46. Kozawa O, Blume-Jensen P, Heldin CH, Rönnstrand L. Involvement of phosphatidylinositol 3′-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release. Eur J Biochem/FEBS. 1997;248(1):149-55. (Pubitemid 27356982)
47. Wang Y, Mo X, Piper MG, Wang H, Parinandi NL, Guttridge D, Marsh CB. M-CSF induces monocyte survival by activating NF-kappaB p65 phosphorylation at Ser276 via protein kinase C. PLoS One. 2011;6(12):e28081. doi: 10.1371/journal.pone.0028081.
48. Lee AW. The role of atypical protein kinase C in CSF-1-dependent Erk activation and proliferation in myeloid progenitors and macrophages. PLoS One. 2011;6(10):e25580. doi: 10.1371/journal.pone.0025580.
49. Kabir NN, Rönnstrand L, Kazi JU. FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL). Med Oncol. 2013;30(1):462. doi: 10.1007/s12032-013-0462-6.
50. Dosil M, Wang S, Lemischka IR. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol. 1993;13(10):6572-85. (Pubitemid 23292651)
51. Arora D, Stopp S, Bohmer SA, Schons J, Godfrey R, Masson K, Razumovskaya E, Rönnstrand L, Tanzer S, Bauer R, Bohmer FD, Muller JP. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. J Biol Chem. 2011;286(13):10918-29. doi: 10.1074/jbc.M110.205021.
52. Barragan M, de Frias M, Iglesias-Serret D, Campas C, Castano E, Santidrian AF, Coll-Mulet L, Cosialls AM, Domingo A, Pons G, Gil J. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol. 2006;80(6):1473-9. doi: 10.1189/jlb.0106041. (Pubitemid 44904986)
53. Komada F, Nishikawa M, Uemura Y, Morita K, Hidaka H, Shirakawa S. Expression of three major protein kinase C isozymes in various types of human leukemic cells. Cancer Res. 1991;51(16):4271-8.
54. Alkan S, Huang Q, Ergin M, Denning MF, Nand S, Maududi T, Paner GP, Ozpuyan F, Izban KF. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol. 2005;79(2):97-106. doi: 10.1002/ajh.20352. (Pubitemid 40770667)
55. Abrams ST, Lakum T, Lin K, Jones GM, Treweeke AT, Farahani M, Hughes M, Zuzel M, Slupsky JR. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood. 2007;109(3):1193-201. doi: 10.1182/blood-2006-03-012021. (Pubitemid 46220668)
56. Klein U, Dalla-Favera R. New insights into the phenotype and cell derivation of B cell chronic lymphocytic leukemia. Curr Top Microbiol Immunol. 2005;294:31-49. (Pubitemid 41491249)
57. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT, Pan Z, Smith LM, Lynch JC, Bociek RG, Bierman PJ, Vose JM, Armitage JO. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol. 2005;18(10):1377-84. doi: 10.1038/modpathol.3800434. (Pubitemid 41348658)
58. Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Prat J, Sierra J. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. Ann Hematol. 2006;85(9):597-603. doi: 10.1007/s00277-006-0144-y. (Pubitemid 44283080)
59. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res. 2001;61(4):1375-81. (Pubitemid 34292559)
60. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol. 1999;145(4):699-711. (Pubitemid 29240849)
61. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15. doi: 10.1056/NEJMra041720. (Pubitemid 40271175)
62. Oellerich T, Bremes V, Neumann K, Bohnenberger H, Dittmann K, Hsiao HH, Engelke M, Schnyder T, Batista FD, Urlaub H, Wienands J. The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85. EMBO J. 2011;30(17):3620-34. doi: 10.1038/emboj.2011.251.
63. Shinohara H, Yasuda T, Aiba Y, Sanjo H, Hamadate M, Watarai H, Sakurai H, Kurosaki T. PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med. 2005;202(10):1423-31. doi: 10.1084/jem.20051591. (Pubitemid 41668744)
64. Kang SW, Wahl MI, Chu J, Kitaura J, Kawakami Y, Kato RM, Tabuchi R, Tarakhovsky A, Kawakami T, Turck CW, Witte ON, Rawlings DJ. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J. 2001;20(20):5692-702. doi: 10.1093/emboj/20.20.5692. (Pubitemid 33010046)
65. Abrams ST, Brown BR, Zuzel M, Slupsky JR. Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells. Blood. 2010;115(22):4447-54. doi: 10.1182/blood-2009-06-229872.
66. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609-14. doi: 10.1182/blood-2002-06-1683. (Pubitemid 35429705)
67. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008;111(5):2685-92. doi: 10.1182/blood-2006-12-062265.
68. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 2007;109(5):2032-9. doi: 10.1182/blood-2006-03-011759. (Pubitemid 46348203)
69. Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Durig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schafer Y, Lampl B, Peschel C, Egle A, Ringshausen I. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell. 2013;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.
70. Kabir NN, Kazi JU. Selective mutation in ATP-binding site reduces affinity of drug to the kinase: a possible mechanism of chemo-resistance. Med Oncol. 2013;30(1):448. doi: 10.1007/s12032-012-0448-9.
71. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov. 2012;11(12):937-57. doi: 10.1038/nrd3871.
72. Ganeshaguru K, Wickremasinghe RG, Jones DT, Gordon M, Hart SM, Virchis AE, Prentice HG, Hoffbrand AV, Man A, Champain K, Csermak K, Mehta AB. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002;87(2):167-76. (Pubitemid 34160623)
73. Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas D, Grever MR. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Exp Hematol. 2001;29(6):703-8. (Pubitemid 32500371)
74. Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood. 2002;99(8):2969-76. (Pubitemid 34525387)
75. Lahn M, Sundell K, Moore S. Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen. Ann N Y Acad Sci. 2003;1002:263-70. (Pubitemid 38253348)
76. Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia. 2006;20(3):514-20. doi: 10.1038/sj.leu.2404113. (Pubitemid 43291752)
77. Best OG, Tam C. Protein Kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy? Leuk Lymphoma. 2013;54(10):2098-9. doi: 10.3109/10428194.2013.779692.
78. Virchis A, Ganeshaguru K, Hart S, Jones D, Fletcher L, Wright F, Wickremasinghe R, Man A, Csermak K, Meyer T, Fabbro D, Champain K, Yap A, Prentice HG, Mehta A. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J. 2002;3(3):131-6. doi: 10.1038/sj.thj.6200165.
79. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs. 2008;17(6):939-44. doi: 10.1517/13543784.17.6.939. (Pubitemid 351864330)
80. Ysebaert L, Morschhauser F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opin Investig Drugs. 2011;20(8):1167-74. doi: 10.1517/13543784.2011.590130.